Shenzhen Salubris Pharmaceuticals (002294) Q3 2026 earnings summary

Executive summary

• 9M 2026 revenue rose 15.47% YoY to ¥3.743bn and attributable net income increased 10.93% to ¥644.2m; expanding commercialization of innovative products supported growth.

• Q3 revenue grew 13.81% YoY to ¥1.264bn and attributable net income rose 19.24% to ¥257.1m.

Financial highlights

• 9M adjusted attributable net income, excluding non-recurring gains and losses, was ¥625.2m, up 10.21% YoY; Q3 was ¥224.2m, up 1.68%.

• 9M operating cash flow was ¥802.5m, up 3.36% YoY; cash and cash equivalents increased ¥147.4m versus a ¥114.9m decrease in the prior-year period.

• 9M total costs and expenses were ¥3.101bn, including selling expenses of ¥1.477bn, R&D expenses of ¥392.8m and administrative expenses of ¥195.7m.

Key financial ratios and metrics

• Basic and diluted EPS were ¥0.23 in Q3, up 21.05% YoY, and ¥0.58 for 9M, up 11.54%.

• Weighted average return on equity was 2.93% for Q3 and 7.23% for 9M; total assets were ¥11.233bn, down 0.58% from year-end, and attributable equity was ¥8.666bn, down 2.99%.